Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZED 1227

Next Previous
Drug Profile

ZED 1227

Alternative Names: TAK-227; ZED-101; ZED-1227

Latest Information Update: 13 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zedira GmbH
  • Developer Dr Falk Pharma; Takeda
  • Class Hepatoprotectants; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Transglutaminase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease; Non-alcoholic fatty liver disease

Most Recent Events

  • 04 Oct 2025 Updated efficacy and adverse events data from a phase IIb trial in Coeliac disease presented at the 33rd United European Gastroenterology Week (UEGW-2025)
  • 05 Jun 2024 Efficacy and safety data from a phase IIb NormaliZED trial in Non-alcoholic fatty liver disease presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 31 Mar 2024 Phase-II clinical trials in Coeliac disease in Australia, Austria, Croatia, Finland, Georgia, Germany, New Zealand, Norway, Poland, Romania, Spain, Sweden, Switzerland and United Kingdom (PO) (NCT07298343) (ISRCTN79155276)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top